MIT Principal Investigator Yuming Liu Joins Atmofizer as Scientific Advisor

VANCOUVER, BC, Jan. 20, 2022 /PRNewswire/ — Atmofizer Technologies Inc. (the “Society” Where “atmovisor“) (CSE: ATMO) (Frankfurt: J3K) is pleased to announce that Yuming Liu is joining the company as a Scientific Advisor. Liu is a Principal Investigator at the Massachusetts Institute of Technology (“MIT“) and expert in sound wave and water technology.

Yuming Liu was co-author of a study by researchers from MIT’s Department of Mechanical Engineering that suggests coronaviruses may be vulnerable to ultrasonic vibrations, in the frequencies used in medical diagnostic imaging, as reported in March 2021 MIT News.1

“We are honored to work with Yuming. His expertise is a tremendous addition to our science team and his involvement is a testament to our technology and the opportunities it brings to the entire industry,” said Olivier Centner, CEO of Atmofizer. “Yuming will help both grow our clean air applications and begin our work on applying our technology to water purification.”

“I am excited to work with Atmofizer and continue their development and research. Atmofizer technology brings a new approach to air and water purification,” said Yuming Liu. “This is a great opportunity to work on a practical solution to the paper I wrote about the ability of ultrasound to destroy COVID. The progress we are making on air purification is very exciting and I am excited to start adapting it to the water.”

MIT News reported that the study results are preliminary and based on limited data regarding the physical properties of the virus. MIT News further reported that how ultrasound might be delivered and its effectiveness in damaging the virus in the complexities of the human body would require further study.. Atmofizer did not participate in or fund any of MIT’s or Yuming’s research. The study is included in this press release for informational purposes only.

For more information, please visit

About Atmofizer Technologies Inc.

Atmofizer’s consumer and industrial solutions are based on its patented and patent-pending technology for the agglomeration and neutralization of ultrafine particles. This capability creates a revolutionary and more efficient method of dealing with the wide range of dangerous nanoparticles, viruses and bacteria that are too small to be effectively handled by conventional HEPA filters and ultraviolet lamps. Atmofizer plans to disrupt the air treatment industry by improving air safety and purification efficiency while reducing operating costs for customers.

Atmofiizing the air refers to the process of using ultrasonic sound waves to agglomerate (cluster) small particles into a larger target which is then irradiated with ultraviolet light to neutralize their harmful properties, making the air you breathe less dangerous to your health. Using units that atmofize the air in tandem with HEPA filters can make HEPA filters more efficient, allow the use of a less powerful filter, and result in a cleaner, longer lasting filter that reduces operating costs. operation and poses fewer health risks. clean or replace.

Atmofizer is the only source of patent-pending, patent-protected technology to atmofize air and applies its proprietary technology in consumer and industrial air purification products currently manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that incorporate Atmofizer technology into their own licensed products. Atmofizer’s owned and licensed product lines include portable, portable and mobile use for personal air handling, as well as larger systems to handle higher air volumes for commercial, industrial, institutional and residential.

Forward-looking information

This press release contains “forward-looking information” within the meaning of applicable securities laws. Any statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some instances, forward-looking information may be identified by words or phrases such as “may”, “will”, “expect”, “probable”, “should”, “would”, “expect”, ” anticipates”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative form of these terms, or other similar words, phrases and grammatical variations, or statements that certain events or conditions “can” or “will” happen, or through policy discussions. Forward-looking information contained herein includes, but is not limited to, the development of the Company’s technology and the Company’s business and strategic plans.

By its nature, forward-looking information is subject to inherent risks and uncertainties which may be general or specific and which give rise to the possibility that the expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that the assumptions are not correct and that the objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information contained in this press release, including, without limitation: the ability to the Company to comply with all applicable governmental regulations, including all applicable laws and regulations; impacts on the Company’s business and operations due to the COVID-19 pandemic; limited operating history; the Company’s ability to access capital to meet its future financing needs; the Company’s dependence on management and key personnel; competetion; changes in consumer trends; foreign currency fluctuations; and general economic, market or business conditions.

Other risk factors may also be found in the Company’s continuous disclosure documents which have been filed on SEDAR and can be viewed at Readers are cautioned to carefully consider these and other factors, uncertainties and potential events and not to place undue reliance on any forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management as of the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise, or to explain any material differences between subsequent actual events and such forward-looking information, except as required by applicable law.

View original content:

SOURCEAtmofizer Technologies Inc.

Comments are closed.